Public reporting burden tor this collection of infomiation is estimated to average 1 liour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, end completing and reviewing this cdiection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for infomnation Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the OfBce of Management and Budget, Papenrork Reduction Prolect (0704-0188), Washington, DC 20503
Original contains color plates: All DTIC reproductions will be in black and white, To identify promoter elements and transcription factors that contribute to enhanced expression of Vascular Endothelial Growth Factor (VEGF) in breast cancer, reporter constructs, encompassing nested deletions approximately every 100 base pairs^ (bp) of the wild type (wt)-promoter (-1175 to -i-50) were synthesized and screened for activity by transient transfection in human breast cancer and mom-mammary cells. In most cells, a drop of > 40% in transcriptional activity was observed under normoxic conditions when sequences between positions -1175 and -1010 were deleted. Sequences downstream of the hypoxia-regulatory element (HRE) at position -971 modulate activity in a tissue-and cell type-specific manner: deletion of sequences between positions -900 and -790 reduces promoter activity another 30%, indicating differences in transcriptional regulation among tissues and within the same cell type. Electrophoretic mobility shift assays (EMSA) revealed that transcription factor Spl, but not AP-2 or Egr-1, binds the basal promoter element upstream of the transcriptional start site between positions -85 and -50. Introduction.
SUBJECT TERMS

INTRODUCTION
Expression of vascular endothelial growth factor (VEGF) is elevated in malignant cells, and clinical studies correlate increased levels of the protein with poor prognosis in breast cancer (1).
Currently little is known about the transcriptional activation of the gene in this particular disease.
We hypothesized that regulation of VEGF at the transcriptional level could be different from other types of cancer. Experiments were designed to identify elements in the wild-type (wt)
VEGF promoter between positions -1200 and +50 that are responsible for increased transcription in breast cancer cells, and to characterize the transcription factors interacting with these
elements. An understanding of how the gene is regulated in this disease could be used as a baseline for developing improved treatment regimens. We plan to synthesize novel expression vectors containing the VEGF promoter elements required for high-level expression in breast cancer cells. Therapeutic genes would thus be expressed specifically in malignant but less so in normal cells. Analysis of all constructs was also conducted in cell lines that were kept under hypoxic conditions (1% O2 for 16 hours) following transfection. Under these conditions the HRE is able to activate transcription several-fold (2). In our experimental setup we observed that this activation depends on cell density, which to our knowledge has not been reported (cell density affects VEGF expression in colon cancer cells under normoxia, i.e. 20% O2 [3] ). Under hypoxic conditions the HRE did not increase transcription in cells kept at < 50% confluence. Overall activity of all constructs was not different from that in control cells kept at normoxia. However, if cells were approximately 90% confluent, increased activity for all constructs was found when compared to that in control cells (in our experimental setup we did not find differences in activity between normoxic high-and low-density conditions). This erratic behavior makes the collection of interpretable data difficult, and currently we have not finished collecting the data under hypoxic conditions.
BODY
However, the data from hypoxic cells collected so far suggest that with the exception of the HRE the same promoter regions are in use under both conditions. Identify and characterize transcription factors that interact at functionally relevant
VEGF promoter regions
This task is comprised of two goals: first, the identification of transcription factors that directly bind functionally important promoter elements using classical molecular techniques, and second, the characterization of transcription factor complexes that assemble at such sequences with matrix assisted laser desorption ionization/time of flight-mass spectroscopy (MALDI/TOF-MS).
To identify transcription factors that interact directly with regulatory important promoter regions we employed electrophoretic mobility shift assays (EMSA). The analysis of the promoter segment that constitutes the basal promoter upstream of the transcriptional start site between positions -85 and -50 was used to optimize the system. This fragment is one of the bestinvestigated promoter segments within the VEGF promoter, is responsible for low-level expression in all cell lines analyzed so far, and contains binding sites for several transcription factors (4-7). The results using nuclear extracts from two breast cancer cell lines are summarized in Figure 3 .
Our results are similar to the ones previously published: as in other cell lines the transcription factor Spl is also the predominant protein interacting at this segment in breast cancer cells. Within the same type of cells, activity could drop another 30% when sequences between positions -900 and -790 were removed.
• A potential negative regulatory element was also identified within the VEGF promoter:
deletion of sequences between positions -790 and -700 restores in part transcriptional activity back, albeit not in all cell lines.
• EMSA with nuclear extracts fi^om human breast cancer cells identified the transcription factor SPl, but not AP-2 or Egr-1, as the only protein binding directly to the basal promoter element upstream of the transcriptional start site. 
CONCLUSIONS
The results so far suggest it to be highly unlikely that promoter elements specific for breast These results also influence Task 3, the construction of gene therapy expression vectors. It seems most feasible now to design and test a minimized promoter that contains only the activating elements, before changes in number and orientation of such elements should be attempted. In comparison to the 1200 bp wt-promoter, a minimzed promoter also allows easier handling and manipulation during the testing for functionality of promoter sites. For one, the necessary mutations can be introduced during its construction. Second, since the activity of such a promoter will also be close to that of the wt-promoter, changes in activity are easier to observe.
For example, were construct pO.l to be used to test the functionality of the three Spl-sites, changes would be small due to the inherent low activity of this construct. With the exception of the HRE, all of the activating sequences can further be tested under normoxic conditions. To resolve the existing experimental problems regarding the activation by hypoxia, we are currently testing whether to include metals such as Cobalt and Manganese in our experimental setup.
These metals are known to mimic hypoxic-like conditions in cells (9), and we have shown in a related project that Manganese induces the wt-VEGF promoter in lung cancer cells under lowdensity conditions.
Since analysis of the basal promoter element by EMS A did not reveal any new information about transcription factor identity and functionality, we mainly used this system to optimize the setup in order to allow future analysis of complex composition and characterization (e.g. posttranslational modifications) by MALDI/TOF-MS at the newly identified, activating promoter elements. To detect tertiary interactions with co-regulators that might get lost during the migration through the gel, we will however, also employ a technique recently described by In all cell lines analyzed, a 40% drop in transcriptional activity to basal promoter activity was observed under normoxic conditions when sequences between positions -1175 and -1010, upstream of the hypoxia-regulatory element (HRE) were deleted. Interestingly, wt-like activity could be restored only in T-47D cells when sequences between positions -1175 and -420 were removed, indicating cell type-specific differences in transcriptional regulation in this disease.
Further, in all cell lines all basal promoter activity was abolished when proximal promoter sequences between positions -100 and -50 were deleted. EMS A revealed two specific transcription factor complexes that bind between positions -88 and -65 in the proximal promoter. Competition experiments showed that the transcription factor Spl, but not AP-2, was present in these complexes. Elucidating the cw-regulating sequences that contribute to the overexpression of VEGF in breast cancer may identify novel regulatory pathways whose modulation could be used to decrease tumor growth.
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